Plasmapheresis Machines Market Size, Share & Trends Analysis Report By Type (Plasma Collection System, Multi-Component Collection System), By Product (Instruments, Disposables), By Technology (Membrane Filtration, Centrifugation), By Application (Extracorporeal Therapy, Plasma Donation), By End-User (Biopharmaceutical Companies, Hospitals and Clinics, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Market Overview

The global plasmapheresis machines market share is expected to grow at a CAGR of 8.56% during the forecast period (2017–2030).

The machine that carries out the plasmapheresis to extract small volumes of blood at a time is known as a plasmapheresis machine. Plasmapheresis is a technique of extracting blood plasma from the body that involves taking blood, separating it into plasma and cells, and then transfusing the cells back into circulation. It is done specifically to eliminate antibodies in the treatment of autoimmune disorders.

Market Dynamics

Top Industry Drivers

Increased Incidences of Chronic Diseases to Surge the Need for Plasmapheresis Machines

Plasmapheresis separates plasma (the liquid component of blood) from blood cells. Typically, plasma is replaced with a different solution, such as albumin or saline, and the plasma is then reintroduced into the patient's body. Plasmapheresis can treat autoimmune illnesses, sickle cell disease, some types of neuropathy, critically ill patients with infections, and other ailments such as Wilson's disease and thrombotic thrombocytopenic purpura.

According to the National Institutes of Health, autoimmune illnesses are the third most frequent cause of chronic illness in the United States, affecting between 5–8% of the population (NIH). Furthermore, according to the British Society for Immunology, various autoimmune disorders are growing at a rate ranging from 3% to 9% year on year. Myasthenia gravis is one such autoimmune disorder (MG). According to the Myasthenia Gravis Foundation of America, MG is the most prevalent neuromuscular primary condition, affecting 14–20 persons out of every 100,000 in the United States.

Furthermore, as per the World Health Organization (WHO) figures, more than 300,000 newborns are born with sickle cell disease each year. Due to the growth in the routine diagnosis of chronic diseases, there is a more significant clinical demand for plasmapheresis operations. Many patients suffering from different autoimmune, trauma, and damage situations require therapeutic plasma exchange to eliminate a disease factor circulating in the plasma. Thus, demand for this equipment is projected to drive the plasmapheresis machines manufacturer.

The High Cost of Procedures to Restrict Plasmapheresis Machines Market Growth

In the United States, the plasmapheresis technique can cost anywhere from USD 5,000 to USD 10,000 per session, and adult plasma treatment in India often costs more than two laths. In some situations, this treatment may need to be repeated, and it will only be helpful if patients have medical insurance that covers such high expenditures. This is an unaffordable alternative for people from low-income families living in emerging nations, and this, combined with adverse reimbursement regulations, is projected to impede market expansion throughout the forecast period.

Emerging Markets to Provide Profitable Opportunities

Emerging economies such as India, China, Brazil, South Korea, and Mexico provide enormous prospects for total market expansion to both existing and new market participants. This is primarily due to continual advances in healthcare infrastructure, lower regulatory hurdles, an increase in the target patient population, and rising healthcare spending. Compared to industrialized countries, regulatory regulations in the Asia-Pacific area are more adaptable and business-friendly.

Due to increased competition in developed regions, leading companies in the plasmapheresis machines market size have shifted their emphasis to emerging areas. For example, in April 2018, B. Braun, a German-based pharmaceutical and medical device business opened five medical production facilities in Penang, Malaysia. In 2017, it established a subsidiary in Zambia. Furthermore, rising awareness of autoimmune illnesses and other blood-related ailments in emerging countries is projected to have a beneficial influence on plasmapheresis equipment, creating significant demand for the plasmapheresis machines market share in the future.

Regional Analysis

Due to the recent spike in the COVID-19 pandemic, the hospitals and clinics segment is likely to gain the most market share. This is primarily due to the increased frequency of therapeutic plasma exchange operations and increased plasma and blood component donations due to COVID-19 infection. Hospitals with in-house transfusion facilities are predicted to improve the most during the forecast period.

Significant Growth in North America and Europe

The American regional market consists of the United States, Canada, Mexico, and other influential nations. It led the global sector in market share and revenue generated by critical enterprises in the region. The rising incidence of chronic illnesses and technological advancements propels this industry forward. However, issues such as the high cost of apheresis equipment and therapeutic plasma exchange procedures and the adoption of a rental model to install apheresis machines are expected to impede market growth during the forecast period.

Plasmapheresis/Plasmapheresis therapy is an important therapeutic option for patients with severe multiple myeloma as supportive care treatment and renal control dysfunction in multiple myeloma. As a result, as the prevalence of various diseases and ailments rises, so does the use of market items. In terms of absolute numbers, Western Europe had the most instances of myeloma for both sexes in 2016–2018, according to a study article published in 2018 by Cowan.

Furthermore, another study survey-based report published in Frontiers in Oncology in 2020 revealed that Western Europe has a much higher ranking in all frequency areas worldwide. According to the Frontiers article, the incidence rate varies from 3 to 6 per 100,000 person-years, and the five-year prevalence ranges from 7 to 14 per 100,000 population.

Segmental Analysis

The plasmapheresis machines market size is segmented into type, application, end-user, and geographic segments. 

Multicomponent Collection Systems (MCCS) is a form of the improved plasma collection system that catches various components of human blood during donation. It is commonly mixed with plasma and other components such as serum, RBCs, and leukocytes. Although some definitions determine multicomponent collection as a technique that results in two different blood components, the vast majority of research publications written by scientists worldwide define multicomponent apheresis as a process that results in the collection of two or more identical or distinct blood components. These multicomponent collections typically use the same centrifugation procedures used for collecting each component individually under various circumstances.

Plasmapheresis is an extracorporeal therapy process because it involves the removal, treatment, return, and exchange of blood plasma/its components from and to the blood circulation. Extracorporeal refers to a medical procedure that is conducted outside of the body. The rising autoimmune disorders, such as thrombotic thrombocytopenic purpura, Goodpasture's syndrome, lupus, Guillain-Barre syndrome, myasthenia gravis, and other chronic illnesses, government reimbursement programs in developed countries, and rising demand for plasma-derived medicines are driving the growth of the extracorporeal therapy segment.

Impact of covid-19

COVID-19 had prompted the World Health Organization to proclaim a worldwide pandemic for public health emergency in March 2020. The pandemic began in December 2019 in Wuhan, China, and quickly escalated from a localized catastrophe to a global pandemic. Several well-known biopharmaceutical and pharmaceutical companies, small businesses, and startups have developed effective therapies for coronavirus infection. 

Currently, no particular medications for their therapy have been authorized. On the other hand, convalescent plasma (CP) treatment has been shown to improve the survival rate of COVID-19 infected patients based on favorable results from various clinical trials. As a result, federal authorities in nations such as the United States and India are coming forward to provide plasma treatment to patients as quickly as feasible while conducting clinical trials to assess the safety and effectiveness of this therapy. For example,

• In May 2020, the National Agency for Medicines and Health Product Safety (ANSM) in France ruled that immune plasma therapy could be used to treat severely sick COVID-19 patients.
• In April 2020, the Indian Council for Medical Research (ICMR) approved establishing a protocol for convalescent plasma therapy trials to treat highly sick COVID-19 patients at the Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST India).

Recent Developments

• April 2021 – Following the expiration of the current term in June 2022, CSL plasma Ltd. announced its intention not to extend its Supply Agreement with Haemonetics to use PCS2 plasma collection system equipment and purchase a disposable plasmapheresis kit in the United States.
• October 2020 – Nigale's plasma separator products were widely used when China started developing convalescent plasma to treat patients infected with COVID-19.
• July 2017 – Haemonetics Corporation received FDA 510(k) clearance for its NexSys PCS plasmapheresis system.